Tags

Type your tag names separated by a space and hit enter

In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
J Infect Chemother 2014; 20(2):77-80JI

Abstract

The neuraminidase inhibitors oseltamivir phosphate (Tamiflu®), zanamivir (Relenza®), laninamivir octanoate (Inavir®), and peramivir (Rapiacta®) have been available for the treatment of influenza in Japan since 2010. To assess the extent of viral resistance, we measured the 50% inhibitory concentration (IC₅₀) of each drug for influenza virus isolates from the 2011-2012 influenza season. Specimens were obtained from patients prior to treatment. Viral isolation was done using Madine-Darby canine kidney cells, and the type and subtype of influenza A(H1N1)pdm09, A(H3N2), or influenza B were determined by RT-PCR using type- and subtype-specific primers. The IC₅₀ was determined by a neuraminidase inhibition assay using a fluorescent substrate. The lineage of influenza B virus was determined by direct sequencing of the hemagglutinin gene. Influenza A(H3N2) and influenza B viruses were isolated in 283 and 42 patients, respectively, while no influenza A(H1N1)pdm09 virus was isolated. No isolate showed an IC₅₀ value exceeding 50 nM for any of the neuraminidase inhibitors. IC50 values for A(H3N2) were similar between the 2010-2011 and 2011-2012 seasons. In contrast, the IC₅₀ values for influenza B viruses in the 2011-2012 season to the four drugs were significantly lower than those found in the 2010-2011 season. These results indicate that the currently epidemic influenza viruses are susceptible to all four neuraminidase inhibitors, with no trend for IC₅₀ values to increase in Japan at present.

Authors+Show Affiliations

Department of Clinical Trials, Center for Advanced Medical Innovation, Kyushu University, Japan; Japan Physicians Association, Tokyo, Japan. Electronic address: hikematsu@camiku.kyushu-u.ac.jp.Japan Physicians Association, Tokyo, Japan.Japan Physicians Association, Tokyo, Japan.Japan Physicians Association, Tokyo, Japan.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24560563

Citation

Ikematsu, Hideyuki, et al. "In Vitro Neuraminidase Inhibitory Activity of Four Neuraminidase Inhibitors Against Influenza Virus Isolates in the 2011-2012 Season in Japan." Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, vol. 20, no. 2, 2014, pp. 77-80.
Ikematsu H, Kawai N, Iwaki N, et al. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan. J Infect Chemother. 2014;20(2):77-80.
Ikematsu, H., Kawai, N., Iwaki, N., & Kashiwagi, S. (2014). In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan. Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, 20(2), pp. 77-80. doi:10.1016/j.jiac.2013.07.002.
Ikematsu H, et al. In Vitro Neuraminidase Inhibitory Activity of Four Neuraminidase Inhibitors Against Influenza Virus Isolates in the 2011-2012 Season in Japan. J Infect Chemother. 2014;20(2):77-80. PubMed PMID: 24560563.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan. AU - Ikematsu,Hideyuki, AU - Kawai,Naoki, AU - Iwaki,Norio, AU - Kashiwagi,Seizaburo, Y1 - 2013/12/11/ PY - 2013/03/27/received PY - 2013/06/12/revised PY - 2013/07/03/accepted PY - 2014/2/25/entrez PY - 2014/2/25/pubmed PY - 2014/11/18/medline KW - 50% Inhibitory concentration KW - Influenza KW - Laninamivir KW - Oseltamivir KW - Peramivir KW - Zanamivir SP - 77 EP - 80 JF - Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy JO - J. Infect. Chemother. VL - 20 IS - 2 N2 - The neuraminidase inhibitors oseltamivir phosphate (Tamiflu®), zanamivir (Relenza®), laninamivir octanoate (Inavir®), and peramivir (Rapiacta®) have been available for the treatment of influenza in Japan since 2010. To assess the extent of viral resistance, we measured the 50% inhibitory concentration (IC₅₀) of each drug for influenza virus isolates from the 2011-2012 influenza season. Specimens were obtained from patients prior to treatment. Viral isolation was done using Madine-Darby canine kidney cells, and the type and subtype of influenza A(H1N1)pdm09, A(H3N2), or influenza B were determined by RT-PCR using type- and subtype-specific primers. The IC₅₀ was determined by a neuraminidase inhibition assay using a fluorescent substrate. The lineage of influenza B virus was determined by direct sequencing of the hemagglutinin gene. Influenza A(H3N2) and influenza B viruses were isolated in 283 and 42 patients, respectively, while no influenza A(H1N1)pdm09 virus was isolated. No isolate showed an IC₅₀ value exceeding 50 nM for any of the neuraminidase inhibitors. IC50 values for A(H3N2) were similar between the 2010-2011 and 2011-2012 seasons. In contrast, the IC₅₀ values for influenza B viruses in the 2011-2012 season to the four drugs were significantly lower than those found in the 2010-2011 season. These results indicate that the currently epidemic influenza viruses are susceptible to all four neuraminidase inhibitors, with no trend for IC₅₀ values to increase in Japan at present. SN - 1437-7780 UR - https://www.unboundmedicine.com/medline/citation/24560563/In vitro_neuraminidase_inhibitory_activity_of_four_neuraminidase_inhibitors_against_influenza_virus_isolates_in_the_2011_2012_season_in_Japan_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1341-321X(13)00006-8 DB - PRIME DP - Unbound Medicine ER -